SRGAP2D

Across TCGA pan-cancer cohorts, SRGAP2D RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SRGAP2D’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SRGAP2D RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SRGAP2D is over-expressed in tumor, although a few such as LUAD and KICH show the opposite, repressed pattern.

KIRC, HNSC, and LIHC are the cancer types where SRGAP2D tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SRGAP2D RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.804	<.001	11	view →
HNSC	All	III,IV	+0.605	<.001	11	view →
LIHC	All	All	+0.370	<.001	5	view →
LUAD	All	All	−0.272	.008	5	view →
KICH	All	All	−0.454	<.001	4	view →
BLCA	All	All	+0.305	.032	4	view →
KIRP	All	III,IV	+0.519	.017	3	view →
CHOL	All	All	+0.313	.009	2	view →
LUSC	Female	III,IV	−0.950	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SRGAP2D–KIRC

Open the KIRC breakdown →